Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
Lang F, Wunderle L, Badura S, Schleyer E, Brüggemann M, Serve H, Schnittger S, Gökbuget N, Pfeifer H, Wagner S, Ashelford K, Bug G, Ottmann OG. Lang F, et al. Among authors: serve h. BMC Pharmacol Toxicol. 2020 Sep 29;21(1):70. doi: 10.1186/s40360-020-00446-x. BMC Pharmacol Toxicol. 2020. PMID: 32993794 Free PMC article. Clinical Trial.
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Löffler H, Sauerland CM, Serve H, Büchner T, Haferlach T, Hiddemann W. Schnittger S, et al. Among authors: serve h. Blood. 2002 Jul 1;100(1):59-66. doi: 10.1182/blood.v100.1.59. Blood. 2002. PMID: 12070009 Free article.
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, Flasshove M, Ottmann OG, Jung W, Cavalli F, Kuse R, Thomalla J, Serve H, O'Farrell AM, Jacobs M, Brega NM, Scigalla P, Hossfeld DK, Berdel WE. Fiedler W, et al. Among authors: serve h. Blood. 2003 Oct 15;102(8):2763-7. doi: 10.1182/blood-2002-10-2998. Epub 2003 Jul 3. Blood. 2003. PMID: 12843001 Free article. Clinical Trial.
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK. Fiedler W, et al. Among authors: serve h. Blood. 2005 Feb 1;105(3):986-93. doi: 10.1182/blood-2004-05-1846. Epub 2004 Sep 30. Blood. 2005. PMID: 15459012 Free article. Clinical Trial.
Treatment of AML in biological subgroups.
Buechner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Schnittger S, Kern W, Tchinda J, Reichle A, Staib P, Ludwig WD, Aul C, Sauerland MC, Heinecke A, Woermann B, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG). Buechner T, et al. Hematology. 2005;10 Suppl 1:281-85. doi: 10.1080/10245330512331390212. Hematology. 2005. PMID: 16276628 Free article. Review. No abstract available.
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, Lengfelder E, Staib P, Ludwig WD, Aul C, Eimermacher H, Balleisen L, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W. Büchner T, et al. Among authors: serve hl. J Clin Oncol. 2006 Jun 1;24(16):2480-9. doi: 10.1200/JCO.2005.04.5013. J Clin Oncol. 2006. PMID: 16735702 Clinical Trial.
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.
Gökbuget N, Hartog CM, Bassan R, Derigs HG, Dombret H, Greil R, Hernández-Rivas JM, Huguet F, Intermesoli T, Jourdan E, Junghanss C, Leimer L, Moreno MJ, Reichle A, Ribera J, Schmid M, Serve H, Stelljes M, Stuhlmann R, Hoelzer D; German Multicenter Study Group for Adult ALL and the European Working Group for Adult ALL. Gökbuget N, et al. Among authors: serve h. Haematologica. 2011 Feb;96(2):238-44. doi: 10.3324/haematol.2010.028092. Epub 2010 Oct 15. Haematologica. 2011. PMID: 20952517 Free PMC article. Clinical Trial.
Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival.
Tickenbrock L, Klein HU, Trento C, Hascher A, Göllner S, Bäumer N, Kuss R, Agrawal S, Bug G, Serve H, Thiede C, Ehninger G, Stadt UZ, McClelland M, Wang Y, Becker A, Koschmieder S, Berdel WE, Dugas M, Müller-Tidow C; Study Alliance Leukemia Group. Tickenbrock L, et al. Among authors: serve h. Leuk Res. 2011 May;35(5):620-5. doi: 10.1016/j.leukres.2010.11.006. Epub 2010 Dec 22. Leuk Res. 2011. PMID: 21176959
374 results